By Mark Watkins Osiris Therapeutics, Inc. (NASDAQ:OSIR) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday, MarketBeat reports. According to Zacks, “Osiris’ third quarter loss was wider-than-expected. The company also said that certain factors